---
title: Adjuncts, Contraindications, and Safety Considerations
version: 1.2
last-updated: 2025-12-07
---

# Adjuncts, Contraindications, and Safety Considerations  
Robot-Assisted Total Knee Arthroplasty (rTKA) – 2025 Update

This document summarizes safety considerations, contraindications, and monitoring requirements for adjunct medications and regional anesthesia used within the rTKA multimodal pathways. Content reflects ERAS Society guidance (2019–2025), ASA/APSF safety statements (2023–2025), and ASRA 2024–2025 anticoagulation guidelines.

---

## 1. Standard Agents & Opioid-Free Adjuncts – Absolute & Relative Contraindications

| Agent | Absolute Contraindications | Relative / Use With Caution | Monitoring & Notes |
|-------|-----------------------------|------------------------------|---------------------|
| **Midazolam** | Known benzodiazepine allergy; acute narrow-angle glaucoma | Severe respiratory disease, myasthenia gravis, sleep apnea (use lower doses 1 mg), advanced age >80, severe hepatic impairment | Standard preoperative anxiolytic across all pathways; does not compromise OFIA principles; typical dose 1–2 mg IV preop; onset 1-3 min, duration 30-60 min |
| **Propofol** | Allergy to propofol, eggs, or soy products | Hemodynamic instability, severe cardiac dysfunction, hypovolemia, severe hypotension (SBP <90) | **UNIVERSAL INDUCTION AGENT:** 1.5-2 mg/kg IV for all three pathways; **TIVA maintenance:** 75-150 mcg/kg/min (alternative to sevoflurane); causes dose-dependent hypotension and respiratory depression; dedicated IV line for infusion |
| **Sevoflurane** | Malignant hyperthermia susceptibility; known volatile anesthetic hypersensitivity; personal or family history of MH | Severe intracranial hypertension, neuromuscular disease (prolonged emergence possible) | **PRIMARY MAINTENANCE OPTION:** 0.8-1.2 MAC for all pathways (alternative to propofol TIVA); easily titratable with favorable recovery profile; well-tolerated in cardiac patients; preferred by many practitioners |
| **Ketamine** | Acute psychosis; uncontrolled schizophrenia; severe uncontrolled hypertension (SBP >180 mmHg) | Uncontrolled HTN (SBP 160-180), severe CAD, recent CVA/TIA (<3 months), history of severe PTSD flashbacks, increased ICP | Avoid induction doses >0.5 mg/kg in CAD; sub-anesthetic infusions (0.1-0.25 mg/kg/hr) have very low psychomimetic risk; may cause transient hypertension and tachycardia |
| **Dexmedetomidine** | High-degree AV block (2°/3° without pacemaker); HR <45 despite anticholinergic; severe bradycardia | Baseline HR <55, hypovolemia, severe LV dysfunction (EF <30%), age >70 | Stop infusion if HR <50 with symptoms; glycopyrrolate 0.2-0.4 mg IV > atropine for bradycardia treatment; hypotension possible in frail patients; avoid large bolus doses |
| **Magnesium sulfate** | Myasthenia gravis; complete heart block; severe renal impairment (CrCl <30 mL/min) | CrCl 30–50 mL/min (reduce dose 25–50%); digitalis therapy (potentiates toxicity) | Infuse over ≥15–20 minutes; monitor reflexes if overdose suspected; enhances NMBD effects (may prolong blockade); typical dose 30-50 mg/kg (40 mg/kg = ~3 g for 70 kg patient) |
| **Lidocaine infusion** (block-free pathway) | Severe hepatic impairment; amide local anesthetic allergy; complete heart block; Wolff-Parkinson-White syndrome | Heart block (1° or 2°), CHF, weight <50 kg, baseline QT prolongation, severe renal disease | Max 2 mg/kg/hr; keep total dose <300 mg; lipid rescue available for LAST; monitor for CNS toxicity (perioral numbness, tinnitus, confusion) |

---

## 2. Regional Anesthesia – ACB + IPACK Contraindications

| Absolute | Relative (Shared Decision-Making) |
|----------|----------------------------------|
| Patient refusal | Local skin infection at injection site |
| Active systemic infection / sepsis | Chronic pain on high-dose opioids (>100 MME/day) |
| Coagulopathy outside ASRA 2024 windows | Baseline sensory or motor deficits in operative limb |
| Allergy to amide local anesthetics (ropivacaine, bupivacaine) | Severe spinal deformity (if neuraxial also considered) |
| | Previous peripheral nerve injury in target area |

### **ASRA 2024-2025 Timing Reference**  
Applicable for deep peripheral blocks (ACB, IPACK - treated like neuraxial):

- **DOACs (rivaroxaban / apixaban / edoxaban):** ≥72 h (CrCl >50 mL/min) / ≥120 h (CrCl <50 mL/min)
- **Dabigatran:** 72–120 h depending on renal function (longer for CrCl <50)
- **Warfarin:** INR ≤1.4  
- **Therapeutic LMWH:** ≥24 h  
- **Prophylactic LMWH:** ≥12 h  
- **Antiplatelets (aspirin, clopidogrel):** Generally safe, no waiting period required per ASRA

**Local anesthetic safety:**  
- Total volume for ACB + IPACK: ~40–50 mL ropivacaine 0.2–0.25%
- Total dose typically 100-125 mg (well below max ~3 mg/kg = 210 mg for 70 kg patient)
- **Lipid emulsion 20% must be immediately available** for LAST management
- Requires readiness for **LAST management** per ASRA guidelines

---

## 3. Opioid-Inclusive Pathway – Relative Contraindications

These patient factors favor choosing OFIA + ACB/IPACK instead of conventional opioid-based pathway:

- **Severe or untreated OSA** (STOP-Bang ≥5 + witnessed apneas)  
- **Obesity hypoventilation syndrome**  
- **COPD or chronic respiratory disease** requiring home O₂  
- **History of post-op respiratory failure** or prolonged ventilation  
- **Neuromuscular disease** (impaired cough/glottic closure)  
- **Frail elderly with high delirium risk** (age >80, cognitive impairment)  
- **History of severe PONV** with prior opioid anesthesia
- **Patient preference for opioid avoidance** after counseling

---

## 4. Agents to Avoid Routinely in rTKA (2024–2025 Consensus)

| Agent | Reason (Evidence Level) | Key References |
|--------|---------------------------|----------------|
| **Gabapentinoids (gabapentin, pregabalin)** | Increase dizziness, delirium, respiratory suppression; provide no additional opioid-sparing benefit in modern multimodal pathways; increased sedation and falls in elderly | Angst 2024; Memtsoudis 2023; ASA/APSF 2024 |
| **Routine intraoperative opioids in opioid-naïve patients** | Higher PONV (2-3x increase), respiratory depression, ileus, delayed mobilization, increased delirium risk in elderly | Soffin 2023; ERAS 2024; Memtsoudis 2019 |
| **High-dose dexamethasone (>10 mg)** | No added analgesic benefit beyond 8-10 mg; unnecessary hyperglycemia risk; no improvement in PONV prophylaxis | De Oliveira 2022; Li 2024 |
| **Large bolus dexmedetomidine loading** | Increased bradycardia and hypotension vs slow infusion; no benefit over 0.5 mcg/kg over 10-20 min | Li 2017; multiple case reports |

---

## 5. Dose Adjustments for Special Populations

### Frail / Older Adults (>70 years, frailty index >0.3)
- **Midazolam:** reduce to **1 mg** or avoid if severe frailty (risk of prolonged sedation, delirium)
- **Propofol:** reduce induction dose to **1-1.5 mg/kg** (increased sensitivity)
- **Ketamine induction:** max **0.3 mg/kg** (reduce psychomimetic risk)
- **Dexmedetomidine infusion:** **0.2–0.4 mcg/kg/hr** (lower range, increased bradycardia risk)
- **Magnesium:** lower end **30 mg/kg** (reduced renal clearance)
- **Sevoflurane:** Consider MAC 0.6-0.8 to minimize delirium risk
- **Opioids:** Reduce by 50% if used (hydromorphone 0.1 mg vs 0.2 mg)

### Cardiac Disease (CAD, HFrEF, Valvular Disease)
- **Propofol:** Use cautiously, slow induction (hypotension risk), consider etomidate alternative
- **Dexmedetomidine:** Avoid rapid bolus, slow infusion only, monitor for bradycardia
- **Ketamine:** Avoid doses >0.3 mg/kg (tachycardia may increase myocardial O2 demand)
- **Sevoflurane:** Well-tolerated in cardiac patients when titrated appropriately (0.8-1.0 MAC)
- **Maintain MAP >65 mmHg**, slow titration of all agents
- **Phenylephrine preferred over ephedrine** for hypotension (less tachycardia)

### Renal Impairment
- **Magnesium:** Reduce dose by 25–50% for CrCl 30–50 mL/min; **avoid if CrCl <30 mL/min**
- **Midazolam:** No dose adjustment needed (hepatic metabolism)
- **Propofol:** No dose adjustment needed
- **Sevoflurane:** No dose adjustment needed
- **Ketamine:** No dose adjustment for mild-moderate renal impairment
- **Dexmedetomidine:** Consider dose reduction in severe renal impairment (reduced clearance)

### Hepatic Impairment
- **Propofol:** Use with caution in severe hepatic disease (reduced clearance)
- **Midazolam:** Reduce dose by 50% in severe hepatic impairment (prolonged duration)
- **Lidocaine infusion:** Contraindicated in severe hepatic impairment (LAST risk)
- **Other agents:** Generally safe with standard dosing

### OSA / Obesity
- **Propofol:** Dose by **lean body weight or ideal body weight** for induction
- **Midazolam:** Use 1 mg only, high risk of respiratory depression
- **Opioids:** Avoid or minimize; if used, enhanced monitoring mandatory
- **Prefer OFIA pathways** for OSA patients (significantly safer)
- **Continuous pulse oximetry** in PACU and floor

---

## 6. Propofol Infusion Syndrome (PRIS) - Rare but Serious

**Risk Factors:**
- Prolonged infusion >48 hours at high doses (>83 mcg/kg/min)
- Not a concern for single rTKA case (<4 hours typical)

**For Reference (not applicable to rTKA protocols):**
- Manifestations: metabolic acidosis, rhabdomyolysis, hyperkalemia, cardiac failure
- Prevention: Avoid prolonged high-dose infusions
- Our protocol uses 75-150 mcg/kg/min for 1-3 hours - well within safe limits

---

## 7. Local Anesthetic Systemic Toxicity (LAST) Preparedness

**Prevention:**
- Keep lipid emulsion 20% **immediately available** in block area and OR
- Max ropivacaine doses: ~3 mg/kg plain, ~7 mg/kg with epinephrine
- Our protocol: ACB 25 mL + IPACK 20 mL of 0.25% = 112.5 mg (safe for >40 kg patient)
- **Negative aspiration before each injection**
- Incremental dosing with frequent aspiration

**Early Recognition:**
- **CNS toxicity:** Perioral numbness, tinnitus, metallic taste, agitation, confusion, slurred speech
- **Cardiovascular toxicity:** Bradycardia, hypotension, arrhythmias, cardiac arrest

**Treatment (ASRA Guidelines):**
1. **Stop local anesthetic injection immediately**
2. **Call for help** - announce "Local anesthetic toxicity"
3. **Manage airway/seizures:**
   - 100% O2, consider intubation
   - Small dose benzodiazepine for seizures (avoid propofol - worsens cardiac toxicity)
4. **Lipid emulsion 20%:**
   - **Bolus:** 1.5 mL/kg lean body weight over 1 minute (~100 mL for 70 kg)
   - **Infusion:** 0.25 mL/kg/min (continue for at least 10 min after circulatory stability)
   - **Repeat bolus** if cardiovascular collapse persists
   - **Max cumulative dose:** ~10 mL/kg over first 30 minutes
5. **ACLS if needed** - prolonged resuscitation may be required, avoid vasopressin

---

## 8. Clinical Pearls

### Standard Agents
- **Midazolam** is standard practice for anxiolysis and does not interfere with OFIA principles
- **Propofol TIVA (75-150 mcg/kg/min)** and **Sevoflurane (0.8-1.2 MAC)** are equally valid maintenance choices
- **Choose Propofol TIVA for:** High PONV risk, MH susceptibility, practitioner preference, smoother emergence in some patients
- **Choose Sevoflurane for:** Ease of titration, hemodynamic stability, established institutional workflow

### OFIA Adjuncts
- **Ketamine** sub-anesthetic doses have minimal psychomimetic effects - safe in OFIA protocols
- **Dexmedetomidine** infusion-only (avoid large bolus) minimizes bradycardia/hypotension
- **Magnesium** provides additional NMDA antagonism and opioid-sparing without significant side effects
- **Lidocaine infusion** optional for block-free pathway - modest additional analgesia

### Regional Blocks
- Regional blocks remain the **gold standard** for rTKA analgesia when not contraindicated
- ACB + IPACK provides **superior analgesia** with motor-sparing (enables early mobilization)
- All protocols should maintain **flexibility** based on patient-specific factors and practitioner preference

### Safety Priorities
- **LAST preparedness** is mandatory when performing blocks (lipid emulsion immediately available)
- **Enhanced monitoring** for opioid-based pathway (respiratory depression, PONV)
- **Glycopyrrolate 0.2-0.4 mg IV preferred** over atropine for dexmedetomidine bradycardia

---

## 9. References
For complete references, see `07_References_Evidence_2024.md`.

**Key safety guidelines:**
- ASRA 2024-2025 Anticoagulation Guidelines
- ASRA LAST Guidelines (Neal 2017, updated 2024)
- ASA/APSF 2024 Guidance on Gabapentinoid Avoidance
- ERAS Society 2024 Updates on Multimodal Analgesia
```
